Share Twitter LinkedIn Facebook Email Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients at Annual Meeting 2018
Promising Phase 2 Results for Zanidatamab in HER2+ Biliary Tract Cancer: ASCO 2024 Update ASCO Annual Meeting 2 Mins Read
Ghassan Abou-Alfa, MD – HIMALAYA Phase III trial – Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.m4v Liver 3 Mins Read